HCW Biologics Third Quarter 2024 Earnings US0.10 loss per share
HCWB Stock | USD 8.95 0.75 9.15% |
About 55% of HCW Biologics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding HCW Biologics suggests that some traders are interested. The current market sentiment, together with HCW Biologics' historical and current headlines, can help investors time the market. In addition, many technical investors use HCW Biologics stock news signals to limit their universe of possible portfolio assets.
HCW Biologics Third Quarter 2024 Results Key Financial Results Revenue US426.4k down 50 percent from 3Q...
Read at simplywall.st
![]() |
HCW Biologics Fundamental Analysis
We analyze HCW Biologics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of HCW Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of HCW Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Sales
Price To Sales Comparative Analysis
HCW Biologics is currently under evaluation in price to sales category among its peers. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
HCW Biologics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with HCW Biologics stock to make a market-neutral strategy. Peer analysis of HCW Biologics could also be used in its relative valuation, which is a method of valuing HCW Biologics by comparing valuation metrics with similar companies.
Peers
HCW Biologics Related Equities
STTK | Shattuck Labs | 11.11 | ||||
PEPG | PepGen | 7.69 | ||||
IPSC | Century Therapeutics | 7.69 | ||||
PHVS | Pharvaris | 4.09 | ||||
PMVP | Pmv Pharmaceuticals | 3.57 | ||||
CSBR | Champions Oncology | 1.11 | ||||
ANEB | Anebulo Pharmaceuticals | 0.99 | ||||
RZLT | Rezolute | 0.28 | ||||
MOLN | Molecular Partners | 0.26 | ||||
MNOV | MediciNova | 5.04 |
Complementary Tools for HCW Stock analysis
When running HCW Biologics' price analysis, check to measure HCW Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HCW Biologics is operating at the current time. Most of HCW Biologics' value examination focuses on studying past and present price action to predict the probability of HCW Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HCW Biologics' price. Additionally, you may evaluate how the addition of HCW Biologics to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Bonds Directory Find actively traded corporate debentures issued by US companies |